Recent Company News

• 05:37 PM ET May 13, 2026
  

  Shionogi & Co. publishes results from SCORPIO-PEP Phase 3 study for ensitrelvir in New England Journal of Medicine (¥2978.0000, 0)

• 07:15 AM ET May 13, 2026
  

  Transcript Intelligence: Shionogi & Co. Q4 Earnings Guidance

• 07:15 AM ET May 13, 2026
  

  Transcript Intelligence: Shionogi & Co. Q4 Earnings Themes

• 07:15 AM ET May 13, 2026
  

  Transcript Intelligence: Shionogi & Co. Q4 Earnings Q&A

• 11:27 PM ET May 12, 2026
  

  Quick Take - Shionogi & Co. trades (6.8%) on OP miss for Q4/guide; zato fails to meet primary endpoint (¥2956.0000, -215)

• 04:07 AM ET May 12, 2026
  

  StreetAccount Metrics Recap - Shionogi & Co. Q4 Earnings (¥3171.0000, 0)

• 02:44 AM ET May 12, 2026
  

  Shionogi & Co. reports Q4 net income attributable ¥46.9B vs FactSet ¥37.50B [4 est, ¥22.40-49.72B] (¥3171.0000, 0)

• 02:18 AM ET Apr 27, 2026
  

  Shionogi & Co. guides year-end DPS ¥38.00 vs prior ¥33.00 (¥3094.0000, -16)

• 06:14 AM ET Apr 08, 2026
  

  Shionogi & Co. reinstated neutral at Goldman Sachs (¥3606.0000, 0)

• 12:20 AM ET Apr 08, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (72 total)